AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE

Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention Patients in a Phase 3 Trial Separate Global Real-World Analyses Show Persistent Gaps in Lipid Management, With Many High-Risk Patients — Company newsroom — sourced from Amgen. Matter furnished by the company. Not a Notice Nearby paid placement. This page reprints a substantial excerpt from the official release. Read the original for the full text. Read the original: https://investors.amgen.com/news-releases/news-release-details/amgens-repathar-reduces-risk-death-patients-high-risk-first